Articles by George Koroneos - Pharmaceutical Executive


Articles by George Koroneos

Pfizer Pulls Leukemia Treatment

Jun 23, 2010

Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs?

Merck Reveals New Trial Network for Oncology

Jun 9, 2010

Merck has established a stable of 15 to 20 investigators focused solely on cancer compounds in an effort to boost efficiency and help move along the bevy of oncology products the firm has in its pipeline.

Physicians Not on the Move

Jun 9, 2010

A new study indicates that doctors are no longer switching offices - largely due to current economic woes. What does this mean for sales reps? Pharm Exec interviews SK&A to find out more about its survey.

Pfizer and Merck: Bullets Dodged

May 5, 2010

In the wake of megamergers and healthcare reform, Pfizer and Merck both produce fairly positive first quarter results

Tech Toys 2: Revenge of the App

May 1, 2010

The new world of mobile applications is sparking creative platforms for reaching consumers and physicians.

Biotech Industry Profits Grow $3.7B

Apr 28, 2010

After a year of losses, the biologics sector got a big boost in profits in 2009. However, with companies holding back on R&D spending and venture capitalists becoming more frugal, can the industry possibly see further growth?

Discussions About Drug User-Fees

Apr 14, 2010

The Prescription Drug User Fee Act will expire in 2012 and FDA is working hard to renegotiate the act before that end date. The contenders: in one corner, the pharma industry; in the other, the general public and consumers - and just about everyone has an opinion about what needs to be changed.

Ad Stars 2010

Pharm Exec presents the architects responsible for some of the year's most memorable and innovative pharmaceutical ads.
Apr 13, 2010

The faces and names behind the year's best pharmaceutical advertising.

Sanofi-Aventis Cuts 400 Jobs

Apr 7, 2010

Sales reps faced another round of layoffs last week as Sanofi-Aventis restructures its sales force due to looming generic competition and a dip in sales.


Click here